Trial · NCT07242456
Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
NCT07242456, Phase 2, Phase 3, Recruiting, First People's Hospital of Hangzhou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication. Trials, record NCT07242456. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07242456
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
- NCT number
- NCT07242456
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 240 participants, estimated
- Lead sponsor
- First People's Hospital of Hangzhou
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Tegoprazan, Amoxicillin, Vonoprazan
- First posted
- 2025-11-21
- Last updated
- 2025-11-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Helicobacter pylori Eradication Rate (ITT and PP) | 4 to 8 weeks after completion of the 14-day treatment regimen | H. pylori eradication will be defined as a negative \^13C-urea breath test performed at the follow-up visit. Eradication rates will be assessed in both the intention-to-treat (ITT) and per-protocol (PP) populations. A participant will be considered eradicated only if the test result is negative without the use of prohibited medications. |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first dose to 2 weeks after completion of treatment (approximately 4 weeks total) | Number and proportion of participants experiencing at least one treatment-emergent adverse event, classified by severity and relationship to study medication. |
| Secondary | Incidence of Serious Adverse Events (SAEs) | From first dose to end of study follow-up (up to 10 weeks) | Number and proportion of participants experiencing at least one serious adverse event, as defined by international regulatory criteria. |
| Secondary | Rate of Treatment Discontinuation Due to Adverse Events | During the 14-day treatment period | Proportion of participants who permanently discontinue the study medication because of adverse events. |
| Secondary | Change in Gastrointestinal Symptom Scores | Baseline to end of 14-day treatment | Change from baseline in gastrointestinal symptom scores (e.g., nausea, bloating, abdominal pain), measured using a standardized symptom questionnaire. |
| Secondary | Medication Adherence Rate | During the 14-day treatment period | Percentage of prescribed doses taken by participants, assessed using pill counts and/or patient diaries. |
| Other | Subgroup Analysis by CYP2C19 Metabolizer Status | At the time of primary eradication assessment (4 to 8 weeks after completion of the 14-day treatment regimen) | If genotyping is performed, participants will be categorized into metabolizer groups (e.g., poor, intermediate, extensive, rapid metabolizers). H. pylori eradication rates will be compared across CYP2C19 phenotypes to explore potential differences in treatment response to P-CAB-based dual therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07242456
GET https://conductscience.org/api/trials/v1/NCT07242456/registered